December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
Inhibition of Choroidal Neovascularization (CNV) by Adeno-Associated Virus (AAV) Mediated Expression of sFLT1
Author Affiliations & Notes
  • F Wang
    School of Optometry and Department of Molecular and Cell Biology University of California Berkeley Berkeley CA
  • K Rendahl
    Gene Therapy Group Chiron Corporation Emeryville CA
  • WC Manning
    Gene Therapy Group Chiron Corporation Emeryville CA
  • D Quiroz
    Gene Therapy Group Chiron Corporation Emeryville CA
  • M Coyne
    Gene Therapy Group Chiron Corporation Emeryville CA
  • SS Miller
    School of Optometry and Department of Molecular and Cell Biology University of California Berkeley Berkeley CA
  • Footnotes
    Commercial Relationships    F. Wang, Chiron Corporation F, P; K. Rendahl, Chiron Corporation E, P; W.C. Manning, Chiron Corporation E, P; D. Quiroz, Chiron Corporation E; M. Coyne, Chiron Corporation E; S.S. Miller, Chiron Corporation F, P. Grant Identification: Support: NIH EY02205, Core Grant EY03176, Chiron Corporation, Foundation Fighting Blindness
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 4602. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      F Wang, K Rendahl, WC Manning, D Quiroz, M Coyne, SS Miller; Inhibition of Choroidal Neovascularization (CNV) by Adeno-Associated Virus (AAV) Mediated Expression of sFLT1 . Invest. Ophthalmol. Vis. Sci. 2002;43(13):4602.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To investigate the anti-angiogenic activity of sFlt1 overexpressed in retinal pigment epithelium (RPE) using an AAV vector with a CMV promoter (AAV-CMV-sFlt1) in a rat model of CNV induced by AAV-VEGF. Methods: sFlt1 was cloned by RT-PCR based techniques from native human fetal RPE cells and packaged into AAV by a triple transfection protocol. Culture medium of 293 cells infected with AAV-sFlt1 was used to inhibit VEGF induced proliferation of human microdermal vascular endothelial cells (HMVEC). The total amount of sFlt1 protein in the conditioned media was determined by a sandwich ELISA. AAV-VEGF+AAV-sFlt1 was co-injected into the subretinal space (SRS) of one eye and AAV-VEGF+AAV-GFP was injected into the SRS of the contralateral eye of Sprague Dawley rats (1010-1011 particles in 2 µl). Pathologic changes in the retina were evaluated by electroretinogram (ERG) and histology. Results: HMVEC proliferation was inhibited by conditioned media from rAAV-sFlt1 infected 293 cells. VEGF (0.1 nM)-induced proliferation was completely inhibited by sFlt1 at 1 nM. Inhibition was also observed at 0.1 nM sFlt1. This inhibition was not seen with HMVEC cells treated with conditioned media from AAV-lacZ infected cells, or cells treated with recombinant VEGF alone (control). Six weeks after injection, ERGs were recorded simultaneously from both eyes of each animal. The ERG a- and b- waves amplitudes were increased about 100% in three animals using AAV-sFlt1. Three months after injection, quantification of CNV was made using histological sections. The extent of neovascularization in the AAV-sFlt1+AAV-VEGF injected eye was 39% smaller than that in AAV-GFP+AAV-VEGF injected eye. Conclusion: Preliminary results show that AAV mediated overexpression of sFlt1 in RPE can inhibit the development of CNV, suggesting that AAV-sFlt1 potentially could be used to inhibit CNV associated with the «wet» form of age-related macular degeneration (AMD).

Keywords: 308 age-related macular degeneration • 346 choroid: neovascularization • 419 gene transfer/gene therapy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×